MCID: RFR007
MIFTS: 24

Refractory Anemia with Excess Blasts in Transformation

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Refractory Anemia with Excess Blasts in Transformation

MalaCards integrated aliases for Refractory Anemia with Excess Blasts in Transformation:

Name: Refractory Anemia with Excess Blasts in Transformation 59 73
Raeb-T 59

Classifications:



External Ids:

Orphanet 59 ORPHA168960
UMLS via Orphanet 74 C0002894 C0280028
ICD10 via Orphanet 34 D46.3
UMLS 73 C0280028

Summaries for Refractory Anemia with Excess Blasts in Transformation

MalaCards based summary : Refractory Anemia with Excess Blasts in Transformation, also known as raeb-t, is related to refractory anemia with excess blasts and refractory anemia. An important gene associated with Refractory Anemia with Excess Blasts in Transformation is CSF3 (Colony Stimulating Factor 3). The drugs Fludarabine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow.

Related Diseases for Refractory Anemia with Excess Blasts in Transformation

Diseases related to Refractory Anemia with Excess Blasts in Transformation via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 refractory anemia with excess blasts 10.6
2 refractory anemia 10.6
3 leukemia 10.4
4 leukemia, acute myeloid 10.3
5 myeloid leukemia 10.3
6 myelodysplastic syndrome 10.0

Graphical network of the top 20 diseases related to Refractory Anemia with Excess Blasts in Transformation:



Diseases related to Refractory Anemia with Excess Blasts in Transformation

Symptoms & Phenotypes for Refractory Anemia with Excess Blasts in Transformation

Drugs & Therapeutics for Refractory Anemia with Excess Blasts in Transformation

Drugs for Refractory Anemia with Excess Blasts in Transformation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
2
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1 33419-42-0 36462
3
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 147-94-4 6253
4
Idarubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 58957-92-9 42890
5 Topoisomerase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
6 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1
9 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1
15
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
17
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
18
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
19
Daunorubicin Approved Phase 2, Phase 3,Phase 3,Phase 1 20830-81-3 30323
20
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
21
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
22
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
23
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
24
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
25
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
26
Hydroxyurea Approved Phase 3 127-07-1 3657
27
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
28
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
29
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
31
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
32
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 104987-11-3 445643 439492
33
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
34
Thioguanine Approved Phase 3 154-42-7 2723601
35
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
36
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
37
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 302-79-4 5538 444795
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
39
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
40 Prednisolone acetate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
41 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
42 Analgesics Phase 3,Phase 2,Phase 1
43 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
45 Methylprednisolone acetate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
46 Methylprednisolone Hemisuccinate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
47 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Gemtuzumab Phase 3,Phase 2
49 Neuroprotective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
50 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 126)
# Name Status NCT ID Phase Drugs
1 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
2 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
3 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
4 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
5 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
6 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
7 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
8 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
11 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
12 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
13 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
14 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
15 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
16 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
17 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
18 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
19 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
20 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
21 A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
22 Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome Unknown status NCT00003123 Phase 2 amifostine trihydrate
23 Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003827 Phase 2 amifostine trihydrate;cytarabine;topotecan hydrochloride
24 Gemtuzumab in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00022321 Phase 2 gemtuzumab ozogamicin
25 Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride
26 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
27 Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy Completed NCT00005942 Phase 1, Phase 2 liposomal daunorubicin citrate;semaxanib
28 Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies Completed NCT00208923 Phase 2 Busulfan, Cyclophosphamide and Fludarabine
29 Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS Completed NCT00744536 Phase 2 Lenalidomide and melphalan
30 Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome Completed NCT00003415 Phase 1, Phase 2 amifostine trihydrate;topotecan hydrochloride
31 Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies Completed NCT01175785 Phase 2 fludarabine phosphate;cyclophosphamide;cyclosporine;mycophenolate mofetil
32 Thalidomide in Treating Patients With Myelodysplastic Syndrome Completed NCT00015990 Phase 2 thalidomide
33 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
34 CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase Completed NCT00084916 Phase 2 temsirolimus
35 Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Completed NCT00004918 Phase 1, Phase 2 Montanide ISA 51 VG
36 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
37 Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes Completed NCT00274781 Phase 2 arsenic trioxide;gemtuzumab ozogamicin
38 Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Completed NCT00055653 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone
39 Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS Completed NCT00053287 Phase 2 carboplatin;fludarabine phosphate;thalidomide;topotecan hydrochloride
40 Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome Completed NCT00003961 Phase 2
41 Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome Completed NCT00077116 Phase 2 busulfan;cyclophosphamide;cytarabine;gemtuzumab ozogamicin;idarubicin
42 FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma Completed NCT00042822 Phase 2 romidepsin
43 Topotecan in Treating Patients With Myelodysplastic Syndrome Completed NCT00003675 Phase 2 topotecan hydrochloride
44 Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome Completed NCT00003171 Phase 2 bryostatin 1
45 Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00008151 Phase 2 cyclosporine;fludarabine phosphate;gemtuzumab ozogamicin;methotrexate;mycophenolate mofetil
46 Decitabine in Treating Patients With Myelodysplastic Syndrome Completed NCT00003361 Phase 2 decitabine
47 Paricalcitol in Treating Patients With Myelodysplastic Syndrome Completed NCT00064376 Phase 2 paricalcitol
48 Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome Completed NCT00732316 Phase 2
49 Bevacizumab in Treating Patients With Myelodysplastic Syndrome Completed NCT00022048 Phase 1, Phase 2
50 Biological Therapy in Treating Patients With Myelodysplastic Syndrome Completed NCT00005853 Phase 2

Search NIH Clinical Center for Refractory Anemia with Excess Blasts in Transformation

Genetic Tests for Refractory Anemia with Excess Blasts in Transformation

Anatomical Context for Refractory Anemia with Excess Blasts in Transformation

MalaCards organs/tissues related to Refractory Anemia with Excess Blasts in Transformation:

41
Myeloid, Bone, Bone Marrow, Endothelial, Kidney, T Cells

Publications for Refractory Anemia with Excess Blasts in Transformation

Articles related to Refractory Anemia with Excess Blasts in Transformation:

(show all 14)
# Title Authors Year
1
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). ( 26400023 )
2015
2
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. ( 12399969 )
2002
3
Re-evaluation of refractory anemia with excess blasts in transformation. ( 11597728 )
2001
4
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. ( 11739159 )
2001
5
Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. ( 10939804 )
2000
6
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. ( 10846828 )
2000
7
Translocation (5;18) in a patient with myelodysplastic syndrome: refractory anemia with excess blasts in transformation. ( 11203251 )
2000
8
Severe hypodiploidy in refractory anemia with excess blasts in transformation. ( 9723043 )
1998
9
Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. ( 9376577 )
1997
10
On a dramatic response of refractory anemia with excess blasts in transformation to 5-azacytidine. ( 7539583 )
1995
11
Trisomy 8 and 11 in refractory anemia with excess blasts in transformation (RAEB-T). ( 1521244 )
1992
12
Trisomy 14 in refractory anemia with excess blasts in transformation. ( 1555198 )
1992
13
Disturbances of T lymphocyte subsets preceding refractory anemia with excess blasts in transformation in a child. ( 3124467 )
1988
14
Duplication of one of the products of the t(8;21) translocation in a patient with refractory anemia with excess blasts in transformation. ( 3802052 )
1987

Variations for Refractory Anemia with Excess Blasts in Transformation

Expression for Refractory Anemia with Excess Blasts in Transformation

Search GEO for disease gene expression data for Refractory Anemia with Excess Blasts in Transformation.

Pathways for Refractory Anemia with Excess Blasts in Transformation

GO Terms for Refractory Anemia with Excess Blasts in Transformation

Sources for Refractory Anemia with Excess Blasts in Transformation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....